Article Text
Abstract
Growth failure is a recognised feature of Gitelman syndrome, although it is not as frequent as in Bartter syndrome. Indometacin is reported to improve growth in Bartter syndrome, but not in Gitelman syndrome, where magnesium supplements are recommended. This paper presents 3 sisters with Gitelman syndrome who could not tolerate magnesium supplements, and whose hypotension and polyuria were eliminated by taking 2 mg/kg/day indometacin, but who grew poorly. However, increasing the indometacin dose to 4 mg/kg/day improved their growth significantly, without changing their symptoms or biochemistry. Gastrointestinal haemorrhage necessitated the use of misoprostol.
- Gitelman syndrome
- Bartter syndrome
- indometacin
- height
- growth
Statistics from Altmetric.com
Footnotes
-
↵* ADC has adopted the Royal Pharmaceutical Society recommendation that journals use the recommended international non-proprietory name (rINN) for medicinal substances, following the recent European directive (92/27/EEC).